Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2024 participants.

Also called NCT05749874

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 2,024 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05749874
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05749874. Randomized; quadruple masking; primary purpose treatment. Start 2023-10-31 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Berberine on Preventing Cardiovascular Disease and Diabetes Mellitus
Acronym
ABCD
Condition
PreDiabetes
Condition
Abdominal Obesity
Condition
Hypertension
Condition
Dyslipidemias
Condition
Atherosclerotic Cardiovascular Disease
Intervention (Drug)
Berberine plus lifestyle intervention
Intervention (Behavioral)
Placebo plus lifestyle intervention
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct05749874
Content hash
59b40460e5934b1801077d25d5b550768e9052b4ae1851f9b4c7d02c92b88ca3